Formulation And In-Vitro Diffusion Studies For Controlled Release Of Nsaid’s

Abstract

Non‐steroidal anti‐inflammatory drugs (NSAIDs) are considered to be the first‐line drugs in the symptomatic
treatment of rheumatoid arthritis, osteoarthritis and spondylitis, Aceclofenac is one of them. It is a newer
derivative of Diclofenac with low gastrointestinal complications. The short biological half‐life (3‐ 4h) and
dosing frequency more than one per day make Aceclofenac an ideal candidate for sustained release. To
reduce the frequency of administration and to improve patient compliance, an once‐daily sustained release
formulation of Aceclofenac is desirable. In the present study an attempt was made to formulate and evaluate
the Nanogel containing Aceclofenac drug. Aceclofenac Nanogel is prepared by solvent diffusion method
(high speed homogenization) using Carbopol 934 and Xanthan gum as polymers. Total seven formulations
were prepared and all were characterized for FTIR studies confirmed that the drug and polymer are
compatible with each other during preparation. The average particle size ranges from 233 nm to273 nm and
the M1 formulation shows -70.9 mV zeta potential. Viscosity studies show all the formulation in the range of
3310 to 3600 cps, and having good viscous property. The drug content studies of formulations were from
81.00 to 92.00%. From the stability studies data, it was found that there was no such difference in drug
content and In-vitro drug release. It shows that the prepared nanogel formulations are stable. Formulation
M1 shows good results for the invitro diffusion studies for controlled release.